Acute hypersensitivity reaction to enfuvurtide upon re-challenge.
Beilke
Mark A
MA
D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000209:etiology; D000077560:Enfuvirtide; D005500:Follow-Up Studies; D015700:HIV Envelope Protein gp41 / Q000009:adverse effects* / Q000627:therapeutic use; D023581:HIV Fusion Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide